Seaport Therapeutics, Inc. - 10-Q Filing

Seaport Therapeutics reports Q3 2026 financial results featuring ongoing R&D expenditures for Glyph and Monash license agreements.

SEC EDGAR ·

Tickers: $SPTX

Read the full article at SEC EDGAR

More Regulatory news